Improving Outcomes for Patients With CML With TKIs: FAQ Podcast

In this episode, Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer questions focused on the optimal selection and management of tyrosine kinase inhibitor (TKI) therapy in patients with CML, with topics including:

• Frontline Management of Chronic-Phase CML
• Selection of TKI Based on Goal of Treatment-Free Remission
• Changing TKIs due to Intolerance: Second-line Therapy and Toxicity Management
• Changing TKIs due to CML Progression: Second-line Therapy and Future Options

Presenters:
Prof. Dr. med Tim Henrik Brümmendorf
Head
Department of Hematology, Oncology, Hematostaseology, and Stem Cell Transplantation
University Hospital Aachen, RWTH Aachen
Aachen, Germany

Jorge Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia, USA

Carlo Gambacorti-Passerini, MD
Professor, Hematology
University Milano Bicocca
Director, Hematology
San Gerardo Hospital
Monza, Italy 

Content based on an online CME program supported by an educational grant from Pfizer Inc.

Link to full program, including associated downloadable slidesets: 
https://bit.ly/30P8Uaf

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.